Skip to main content
. 2020 May 19;11(20):1894–1910. doi: 10.18632/oncotarget.27585

Figure 6. The 4D12G1 mAb inhibits growth of human EOC xenografts.

Figure 6

Human EOC tumors were injected s. c. into immunodeficient mice. When tumors became palpable, mice were injected i. p. with 200 μg of either the 4D12G1 mAb or an isotype control mAb weekly for 5 continuous weeks. Treatment with the 4D12G1 mAb significantly inhibited the growth of OVCAR8 tumors in (A) severely immunodeficient NSG mice (P < 0.001) and in (B) T cell-deficient athymic nude mice (P < 0.0001). More importantly, treatment with the 4D12G1 mAb significantly inhibited the growth of three primary HGSOC tumors (P < 0.0001 in all cases) generated from recently diagnosed patients and xenografted into immunodeficient NSG mice including (C) PDX-4, (D) PDX-6, and (E) PDX-9. (F) Detection of caspase-3 positive cells in the OVCAR8 (upper row) and PDX-4 tumors (lower row) from NSG mice at 20× is shown by arrows in mice treated with the 4D12G1 mAb (right column) compared to mice treated with isotype control mAb (left column). Caspase-3 data shown are representative of three experiments yielding similar results. All error bars indicate ± SD.